Literature DB >> 7854038

Effects of modafinil-induced wakefulness on glutamine synthetase regulation in the rat brain.

M Touret1, M Sallanon-Moulin, C Fages, V Roudier, M Didier-Bazes, B Roussel, M Tardy, M Jouvet.   

Abstract

Changes in the level of glutamine synthetase (GS), an enzyme chiefly found in glial cells, were investigated in the brains of rats treated with modafinil, an awakening drug interfering with central catecholamine function. Two hours (waking period) and 7 h (recovery period) after intra-peritoneal injection of 128 mg/kg modafinil, a significant increase in the level of GS protein was observed by immunotitration in both the locus coeruleus (+30%) and in the frontoparietal cortex (+50%). No changes were observed with 64 mg/kg of modafinil. GS mRNA was quantified in the entire cortex by Northern blot hybridization using an oligonucleotidic GS cDNA probe. A significant increase in the GS-mRNA level (+70%) was observed in the CX of rats 2 h after injection of 128 mg/kg modafinil; the level tended to return to control values 7 h later during the recovery period. The level of glial acid fibrillary protein (GFAP), an astroglial marker, was unchanged after modafinil treatment. These changes in GS levels after modafinil treatment are discussed in terms of neuron-glia interactions in the regulation of brain metabolism during pharmacologically induced wakefulness, excluding possible stress effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7854038     DOI: 10.1016/0169-328x(94)90082-5

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  9 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

2.  New medications for the treatment of cocaine dependence.

Authors:  Kyle M Kampman
Journal:  Psychiatry (Edgmont)       Date:  2005-12

3.  Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques.

Authors:  Anushka V Goonawardena; Stephen R Morairty; Ryan Dell; Gabriel A Orellana; Marius C Hoener; Tanya L Wallace; Thomas S Kilduff
Journal:  Neuropsychopharmacology       Date:  2019-04-06       Impact factor: 7.853

Review 4.  What's new in the treatment of cocaine addiction?

Authors:  Kyle M Kampman
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

5.  A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence.

Authors:  Kyle M Kampman; Kevin G Lynch; Helen M Pettinati; Kelly Spratt; Michael R Wierzbicki; Charles Dackis; Charles P O'Brien
Journal:  Drug Alcohol Depend       Date:  2015-08-14       Impact factor: 4.492

Review 6.  The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.

Authors:  Maddalena Mereu; Antonello Bonci; Amy Hauck Newman; Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2013-08-10       Impact factor: 4.530

Review 7.  Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants.

Authors:  Heinz Steiner; Vincent Van Waes
Journal:  Prog Neurobiol       Date:  2012-10-17       Impact factor: 11.685

8.  Deletion of Trace Amine-Associated Receptor 1 Attenuates Behavioral Responses to Caffeine.

Authors:  Michael D Schwartz; Jeremiah B Palmerston; Diana L Lee; Marius C Hoener; Thomas S Kilduff
Journal:  Front Pharmacol       Date:  2018-02-02       Impact factor: 5.810

Review 9.  The treatment of cocaine use disorder.

Authors:  Kyle M Kampman
Journal:  Sci Adv       Date:  2019-10-16       Impact factor: 14.136

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.